The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

Therapeutic Advances in Hematology

Volumn 5, Issue 6, 2014, Pages 197-210

  Andreu Vieyra, Claudia V ^a   Berenson, James R ^b  

^a Oncotherapeutics ^*  (United States)

^b INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

histone deacetylase inhibitor; multiple myeloma; panobinostat

Indexed keywords

EID: 84993729247     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714552614     Document Type: Review

References (74)

1. Aronson L. Davies F. (2012) DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 97: 1119–1130.
2. Atadja P. (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233–241.
3. Berdeja J. Mace J. Lamar R. Gian V. Murphy P. Patel M. et al. (2012) A single-arm, open-label, multicenter phase I / II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed / refractory multiple myeloma (RR MM). J Clin Oncol 30: TPS8115.
4. Berdeja J. Savona M. Mace J. Hart L. Essell J. Owera R. et al. (2013) A single-arm, open-label, multi-center phase I / II study of the combination of panobinostat and carfilzomib in patients (pts) with relapsed or relapse / refractory multiple myeloma (MM). Blood 122: 1937.
5. Berenson J. Hilger J. Yellin O. Boccia R. Matous J. Dressler K. et al. (2014) A phase 1 / 2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 93: 88–98.
6. Biran N. Shahnaz S. Jagannath S. Cho H. Osman K. Parekh S. et al. (2013) A phase II, single-center, open-label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma. Blood 122: 5392.
7. Botbol V. Scornik O. (1991) Measurement of instant rates of protein degradation in the livers of intact mice by the accumulation of bestatin-induced peptides. J Biol Chem 266: 2151–2157.
8. Brenner H. Gondos A. Pulte D. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111: 2521–2526.
9. Bruzzese F. Pucci B. Milone M. Ciardiello C. Franco R. Chianese M. et al. (2013) Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis 4: e878.
10. Campbell R. Sanchez E. Steinberg J. Shalitin D. Li Z. Chen H. et al. (2010) Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 84: 201–211.
11. Cashen A. Juckett M. Jumonville A. Litzow M. Flynn P. Eckardt J. et al. (2012) Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 91: 33–38.
12. Catley L. Weisberg E. Kiziltepe T. Tai Y. Hideshima T. Neri P. et al. (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH 589 are synergistic in myeloma cells. Blood 108: 3441–3449.
13. Catley L. Weisberg E. Tai Y. Atadja P. Remiszewski S. Hideshima T. et al. (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102: 2615–2622.
14. Cenci S. (2012) The proteasome in terminal plasma cell differentiation. Semin Hematol 49: 215–222.
15. de Angelo D. Spencer A. Bhalla K. Prince H. Fischer T. Kindler T. et al. (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27: 1628–1636.
16. Feng R. Oton A. Mapara M. Anderson G. Belani C. Lentzsch S. (2007) The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139: 385–397.
17. Finazzi G. Vannucchi A. Martinelli V. Ruggeri M. Nobile F. Specchia G. et al. (2013) A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol 161: 688–694.
18. Gao L. Cueto M. Asselbergs F. Atadja P. (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748–25755.
19. Giles F. Fischer T. Cortes J. Garcia-Manero G. Beck J. Ravandi F. et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628–4635.
20. Hajek R. Siegel D. Orlowski R. Ludwig H. Palumbo A. Dimopoulos M. (2014) The role of HDAC inhibitors in patients with relapsed / refractory multiple myeloma. Leuk Lymphoma 55: 11–18.
21. Harrison S. Quach H. Link E. Seymour J. Ritchie D. Ruell S. et al. (2011) A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118: 6274–6283.
22. Hideshima T. Anderson K. (2012) Biologic impact of proteasome inhibition in multiple myeloma cells–from the aspects of preclinical studies. Semin Hematol 49: 223–227.
23. Hideshima T. Bradner J. Wong J. Chauhan D. Richardson P. Schreiber S. et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102: 8567–8572.
24. Jankowska E. Stoj J. Karpowicz P. Osmulski P. Gaczynska M. (2013) The proteasome in health and disease. Curr Pharm Des 19: 1010–1028.
25. Kale A. Moore B. (2012) Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 55: 10317–10327.
26. Kalushkova A. Fryknäs M. Lemaire M. Fristedt C. Agarwal P. Eriksson M. et al. (2010) Polycomb target genes are silenced in multiple myeloma. PloS ONE 5: e11483.
27. Khan O. La Thangue N. (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85–94.
28. Khot A. Dickinson M. Prince H. (2013) Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 22: 1211–1223.
29. Kikuchi J. Wada T. Shimizu R. Izumi T. Akutsu M. Mitsunaga K. et al. (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116: 406–417.
30. Kumar S. Rajkumar S. Dispenzieri A. Lacy M. Hayman S. Buadi F. et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516–2520.
31. Lavelle D. Chen Y. Hankewych M. de Simone J. (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68: 170–178.
32. Lemaire M. Fristedt C. Agarwal P. Menu E. van Valckenborgh E. de Bruyne E. et al. (2012) The HDAC inhibitor LBH 589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clin Cancer Res 18: 2230–2239.
33. Maes K. Menu E. van Valckenborgh E. van Riet I. Vanderkerken K. de Bruyne E. (2013) Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers 5: 430–461.
34. Maiso P. Carvajal-Vergara X. Ocio E. López-Pérez R. Mateo G. Gutiérrez N. et al. (2006) The histone deacetylase inhibitor LBH 589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66: 5781–5789.
35. Mannava S. Zhuang D. Nair J. Bansal R. Wawrzyniak J. Zucker S. et al. (2012) KLF 9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119: 1450–1458.
36. Mateos M. Ocio E. San Miguel J. (2013) Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol 40: 618–633.
37. Mateos M. Spencer A. Taylor K. Lonial S. de La Rubia J. Facon T. et al. (2010) Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). J Clin Oncol 28: 8030.
38. Matthews G. Lefebure M. Doyle M. Short J. Ellul J. Chesi M. et al. (2013) Preclinical screening of histone deacetylase inhibitors combined with ABT-737. rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis 4: e798.
39. Mithraprabhu S. Khong T. Jones S. Spencer A. (2013) Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol 162: 559–562.
40. Moore H. Davenport E. Smith E. Muralikrishnan S. Dunlop A. Walker B. et al. (2009) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 8: 762–770.
41. Morgan G. (1999) Advances in the biology and treatment of myeloma. Br J Haematol 105: 4–6.
42. Müller B. Jana L. Kasajima A. Lehmann A. Prinzler J. Budczies J. et al. (2013) Differential expression of histone deacetylases HDAC 1, 2 and 3 in human breast cancer–overexpression of HDAC 2 and HDAC 3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13: 215.
43. Neri P. Bahlis N. Lonial S. (2012) Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 21: 733–747.
44. New M. Olzscha H. La Thangue N. (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6: 637–656.
45. Niegisch G. Knievel J. Koch A. Hader C. Fischer U. Albers P. et al. (2013) Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol 31: 1770–1779.
46. Niesvizky R. Ely S. Mark T. Aggarwal S. Gabrilove J. Wright J. et al. (2011) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117: 336–342.
47. Ocio E. Vilanova D. Atadja P. Maiso P. Crusoe E. Fernández-Lázaro D. et al. (2010) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95: 794–803.
48. Offidani M. Polloni C. Cavallo F. Liberati A. Ballanti S. Pulini S. et al. (2012) Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed / refractory multiple myeloma. Leuk Lymphoma 53: 1722–1727.
49. Orlowski R. (2013) Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 40: 634–651.
50. Pei X. Dai Y. Grant S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839–3852.
51. Petta V. Gkiozos I. Strimpakos A. Syrigos K. (2013) Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol 72: 935–952.
52. Prince H. Bishton M. Harrison S. (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958–3969.
53. Pulte D. Redaniel M. Brenner H. Jansen L. Jeffreys M. (2014) Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma 55: 1083–1089.
54. Quintás-Cardama A. Kantarjian H. Estrov Z. Borthakur G. Cortes J. Verstovsek S. (2012) Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 36: 1124–1127.
55. Rasheed W. Bishton M. Johnstone R. Prince H. (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8: 413–432.
56. Richardson P. Alsina M. Weber D. Coutre S. Lonial S. Gasparetto C. et al. (2012) PANORAMA 2: panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood 120: 1852.
57. Richardson P. Schlossman R. Alsina M. Weber D. Coutre S. Gasparetto C. et al. (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122: 2331–2337.
58. Ropero S. Esteller M. (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19–25.
59. Sanchez E. Shen J. Steinberg J. Li M. Wang C. Bonavida B. et al. (2011) The histone deacetylase inhibitor LBH 589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 35: 373–379.
60. San-Miguel J. Moreau P. Yoon S. Dimopoulos M. de Moraes Hungria V. Jedrzejczak W. et al. (2012) Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). J Clin Oncol 30: e18572.
61. San-Miguel J. Richardson P. Günther A. Sezer O. Siegel D. Bladé J. et al. (2013) Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31: 3696–3703.
62. Santo L. Hideshima T. Kung A.L. Tseng J. Tamang D. Yang M. et al. (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC 6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119: 2579–2589.
63. Schlossman R. Alsina M. Weber D. Coutre S. Gasparetto C. Mukhopadhyay S. et al. (2013) Time to event analyses in PANORAMA 2: a phase 2 study of panobinostat, bortezomib, and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood 122: 1970.
64. Shah J. Thomas S. Weber D. Wang M. Alexanian R. Qazilbash M. et al. (2012) Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and / or refractory multiple myeloma. Blood 120: 4081.
65. Sharma S. Beck J. Mita M. Paul S. Woo M. Squier M. et al. (2013) A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs 31: 974–985.
66. Siegel R. Ma J. Zou Z. Jemal A. (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9–29.
67. Simms-Waldrip T. Rodriguez-Gonzalez A. Lin T. Ikeda A. Fu C. Sakamoto K. (2008) The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 94: 283–286.
68. Smith M. Newland A. (1999) Treatment of myeloma. QJM 92: 11–14.
69. Stenzinger A. Endris V. Klauschen F. Sinn B. Lorenz K. Warth A. et al. (2013) High SIRT 1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 13: 450.
70. Treppendahl M. Kristensen L. Grønbæk K. (2014) Predicting response to epigenetic therapy. J Clin Invest 124: 47–55.
71. van Damme M. Crompot E. Meuleman N. Mineur P. Bron D. Lagneaux L. et al. (2012) HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7: 1403–1412.
72. Ververis K. Hiong A. Karagiannis T. Licciardi P. (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7: 47–60.
73. West A. Johnstone R. (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124: 30–39.
74. Wolf J. Siegel D. Goldschmidt H. Hazell K. Bourquelot P. Bengoudifa B. et al. (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed / refractory multiple myeloma. Leuk Lymphoma 53: 1820–1823.